Streetbeat News

Stock Prices

A

CELH

CRM

DKNG

HRL

IOT

MDB

NOW

NTNX

SNOW

The article highlights the ten large-cap stocks that were the worst performers last week, including MongoDB, Nutanix, DraftKings, Salesforce, Samsara, Celsius Holdings, Agilent Technologies, Snowflake, ServiceNow, and Hormel Foods. The declines were driven by weak guidance, earnings results, tax hikes, and other factors.

Portfolio Pulse from Lekha Gupta

June 02, 2024 | 3:12 pm

BNTX

GMAB

Genmab A/S and BioNTech SE announced promising Phase 2 trial data for their investigational bispecific antibody acasunlimab in combination with pembrolizumab, showing a 12-month overall survival rate of 69% in patients with previously treated metastatic non-small cell lung cancer.

Portfolio Pulse from Charles Gross

June 02, 2024 | 3:02 pm

BBY

BIRK

BURL

CAVA

DKS

HPQ

MRO

NIO

ONON

RL

Ten stocks, including NIO and Best Buy, were the best performers last week. Key drivers included strong earnings reports, raised guidance, and analyst upgrades.

Portfolio Pulse from Lekha Gupta

June 02, 2024 | 2:57 pm

SPY

USO

OPEC+ has agreed to extend all production curbs into 2025 in an effort to boost oil prices, as reported by The Wall Street Journal.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:54 pm

BA

The launch of Boeing's Starliner spacecraft was delayed on Saturday due to a computer system issue, minutes before takeoff.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:51 pm

BCRX

BioCryst Pharmaceuticals announced new data showing that patients with hereditary angioedema (HAE) with normal C1-inhibitor levels experienced reduced attack rates after starting ORLADEYO treatment. The data were presented at the EAACI Congress in Valencia, Spain.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:46 pm

NBTX

Nanobiotix (NASDAQ:NBTX) presented new data at ASCO 2024 from their Phase 1 Study 1100, showing promising results for their radiotherapy-activated NBTXR3 followed by anti-PD-1 immune checkpoint inhibitors in patients with advanced solid and metastatic tumors. The study showed a 48% ORR in anti-PD-1 naïve patients and a 28% ORR in anti-PD-1 resistant patients.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:42 pm

NTLA

Intellia Therapeutics announced that a single dose of NTLA-2002 led to a 98% mean reduction in monthly hereditary angioedema (HAE) attack rates, with an average follow-up of over 20 months. The data, presented at the EAACI Congress 2024, showed that 8 out of 10 patients remained attack-free and all patients who discontinued prophylaxis treatment remained free of chronic prophylaxis. The therapy demonstrated a favorable safety and tolerability profile.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:38 pm

GILD

RCUS

Gilead Sciences and Arcus Biosciences announced that their combination therapy significantly reduced the risk of death and disease progression in third-line metastatic colorectal cancer patients in a Phase 1b/2 trial. The results will be presented at the 2024 ASCO Annual Meeting.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:36 pm

AZN

AstraZeneca announced that its drug Imfinzi significantly reduces the risk of death by 27% compared to placebo in a global Phase III trial for limited-stage small cell lung cancer. The trial results showed a 57% survival rate at three years and will be presented at the 2024 ASCO Annual Meeting.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:16 pm